Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
暂无分享,去创建一个
J. Wargo | P. Sharma | A. Ribas | J. Blando | J. Allison | S. Subudhi | L. Vence | Anu Sharma | J. Scutti | Padmanee Sharma
[1] Angela E. Leek,et al. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies , 2018, Cancer cell.
[2] Christopher A. Lazarski,et al. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy , 2018, Cell Research.
[3] A. Bertoletti,et al. CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes , 2016, Scientific Reports.
[4] L. Butterfield,et al. Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab , 2016, Journal of Immunotherapy for Cancer.
[5] M. Glennie,et al. Influence of immunoglobulin isotype on therapeutic antibody function. , 2016, Blood.
[6] A. Ribas,et al. Combination cancer immunotherapies tailored to the tumour microenvironment , 2016, Nature Reviews Clinical Oncology.
[7] C. Meyer,et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients , 2015, Proceedings of the National Academy of Sciences.
[8] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.
[9] J. Wolchok,et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.
[10] Michael R. Green,et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. , 2013, The Journal of clinical investigation.
[11] Sean C. Bendall,et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia , 2013, Nature Biotechnology.
[12] A. Korman,et al. Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells , 2013, Cancer Immunology Research.
[13] Christopher M. Jackson,et al. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer , 2013, Journal of Translational Medicine.
[14] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[15] A. Ribas,et al. CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans , 2011, Clinical Cancer Research.
[16] A. Ribas. Clinical development of the anti-CTLA-4 antibody tremelimumab. , 2010, Seminars in oncology.
[17] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[18] J. Wolchok,et al. Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial , 2010, Clinical Cancer Research.
[19] Joonsoo Kang,et al. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity , 2010, Proceedings of the National Academy of Sciences.
[20] S. Quezada,et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies , 2009, The Journal of experimental medicine.
[21] B. Comin-Anduix,et al. Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade , 2009, Clinical Cancer Research.
[22] T. Nomura,et al. CTLA-4 Control over Foxp3+ Regulatory T Cell Function , 2008, Science.
[23] P. Sharma,et al. CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients , 2008, Proceedings of the National Academy of Sciences.
[24] B. Kavanagh,et al. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. , 2008, Blood.
[25] D. Neuberg,et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients , 2008, Proceedings of the National Academy of Sciences.
[26] A. Rudensky,et al. Foxp3 in control of the regulatory T cell lineage , 2007, Nature Immunology.
[27] Loise M. Francisco,et al. Blockade of CTLA-4 on CD4+CD25+ Regulatory T Cells Abrogates Their Function In Vivo1 , 2006, The Journal of Immunology.
[28] J. Stroud,et al. FOXP3 Controls Regulatory T Cell Function through Cooperation with NFAT , 2006, Cell.
[29] S. Quezada,et al. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. , 2006, The Journal of clinical investigation.
[30] T. Mak,et al. Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4 , 2000, The Journal of experimental medicine.
[31] J. Allison,et al. Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.
[32] J. Allison,et al. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.
[33] P. Linsley,et al. CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.
[34] P. Chinn,et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.